Edition:
United Kingdom

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

101.30EUR
1:55pm GMT
Change (% chg)

€-1.00 (-0.98%)
Prev Close
€102.30
Open
€103.70
Day's High
€104.00
Day's Low
€100.90
Volume
71,779
Avg. Vol
199,381
52-wk High
€124.90
52-wk Low
€70.55

Latest Key Developments (Source: Significant Developments)

Morphosys Says Its Licensee Janssen Has Expanded Clinical Development Of Guselkumab Into Ulcerative Colitis
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - MorphoSys AG ::MORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN HAS EXPANDED CLINICAL DEVELOPMENT OF GUSELKUMAB (TREMFYA(R)) INTO ULCERATIVE COLITIS.MORPHOSYS AG- JANSSEN HAS INITIATED A PROOF-OF-CONCEPT PHASE 2A CLINICAL TRIAL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS .MORPHOSYS IS ELIGIBLE TO CERTAIN MILESTONE PAYMENTS AND RECEIVES ROYALTIES ON NET SALES OF TREMFYA (R).  Full Article

Morphosys Licensee Janssen Announces Psoriasis Data
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - MorphoSys AG ::MORPHOSYS'S LICENSEE JANSSEN ANNOUNCES DATA FROM PHASE 3 HEAD-TO-HEAD STUDY ECLIPSE DEMONSTRATING SUPERIORITY OF TREMFYA(R) VERSUS. COSENTYX(R) AS MEASURED BY PASI 90 AT WEEK 48 IN TREATMENT OF PLAQUE PSORIASIS.LICENSEE JANSSEN HAS ANNOUNCED THAT RESULTS FROM ECLIPSE STUDY DEMONSTRATED THAT TREMFYA^(R) (GUSELKUMAB) WAS SUPERIOR TO COSENTYX^(R) (SECUKINUMAB) IN TREATING ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS FOR PRIMARY ENDPOINT OF A PASI 90 RESPONSE AT WEEK 48.  Full Article

Morphosys - Guselkumab Shows Superior Responses To Secukinumab In The Treatment Of Psoriasis
Friday, 7 Dec 2018 

Dec 7 (Reuters) - MorphoSys AG ::DGAP-ADHOC: AD HOC: MORPHOSYS ANNOUNCES THAT ACCORDING TO A PRESENTATION TITLE AT AN UPCOMING CONFERENCE, GUSELKUMAB DEMONSTRATES SUPERIOR LONG-TERM RESPONSES TO SECUKINUMAB AT WEEK 48 IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS.MORPHOSYS EXPECTS THAT THIS ANNOUNCEMENT RELATES TO AN UPCOMING PRESENTATION OF CLINICAL DATA FROM SO CALLED "ECLIPSE" CLINICAL STUDY.ECLIPSE TRIAL HAS BEEN CONDUCTED BY MORPHOSYS' LICENSEE JANSSEN, COMPARING EFFICACY OF GUSELKUMAB TREMFYA^(R) TO SECUKINUMAB COSENTYX^(R), FOR TREATMENT OF ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS, AT WEEK 48.TREMFYA^(R) IS A HUMAN ANTI-IL-23 MONOCLONAL ANTIBODY DEVELOPED BY JANSSEN THAT WAS GENERATED UTILIZING MORPHOSYS' PROPRIETARY HUCAL ANTIBODY TECHNOLOGY.  Full Article

I-Mab Biopharma, Morphosys Announce China IND Submission Of TJ202/MOR202
Wednesday, 8 Aug 2018 

Aug 7 (Reuters) - MorphoSys AG ::I-MAB BIOPHARMA AND MORPHOSYS ANNOUNCE CHINA IND SUBMISSION OF TJ202/MOR202.MORPHOSYS AG- I-MAB HAS SUBMITTED AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO CHINA NATIONAL DRUG ADMINISTRATION (CNDA) FOR TJ202/MOR202.  Full Article

Germany's Morphosys Has Lower Q2 Sales, Greater Oper. Loss
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - MorphoSys AG ::DGAP-NEWS: MORPHOSYS AG REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE 8.1 MILLION EUR VERSUS 11.7 MILLION EUR YEAR AGO.MORPHOSYS IS INCREASING ITS FINANCIAL GUIDANCE FOR 2018, EXPECTING REVENUES OF BETWEEN EUR 67 AND 72 MILLION, EBIT OF EUR -55 TO -65 MILLION.MORPHOSYS- CO AND GALAPAGOS ENTERED INTO GLOBAL LICENSE AGREEMENT WITH NOVARTIS FOR MOR106; CO AND GALAPAGOS TO JOINTLY RECEIVE UP-FRONT PAYMENT OF EUR 95 MILLION.CASH POSITION INCREASED TO EUR 450.5 MILLION AS OF JUNE 30, 2018.EARNINGS BEFORE INTEREST AND TAXES (EBIT) IN Q2 2018 AMOUNTED TO EUR -24.1 MILLION (Q2 2017: EUR -15.4 MILLION).2018 EXPENSES FOR PROPRIETARY DEVELOPMENT AND TECHNOLOGY DEVELOPMENT ARE EXPECTED TO BE IN A CORRIDOR OF EUR 87 TO 97 MILLION.  Full Article

Morphosys And Galapagos Sign Global License Agreement For Mor106 With Pharma Partner
Thursday, 19 Jul 2018 

July 19 (Reuters) - GALAPAGOS NV ::REG-MORPHOSYS AND GALAPAGOS SIGN GLOBAL LICENSE AGREEMENT FOR MOR106 WITH TOP PHARMA PARTNER.EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH NOVARTIS ON MOR106.UP-FRONT PAYMENT OF EUR 95 MILLION (USD 111 MILLION*) AND POTENTIAL MILESTONE PAYMENTS OF UP TO APPROXIMATELY EUR 850 MILLION (USD 1 BILLION*).NOVARTIS TO BEAR ALL FUTURE RESEARCH, DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION COSTS.AGREEMENT BETWEEN MORPHOSYS, GALAPAGOS, AND NOVARTIS IS SUBJECT TO CLEARANCE BY US ANTITRUST AUTHORITIES UNDER HART-SCOTT-RODINO ACT.ROYALTIES UP TO LOW-TEENS TO LOW-TWENTIES.  Full Article

Annual General Meeting Of Morphosys AG Elects New Supervisory Board Members
Thursday, 17 May 2018 

May 17 (Reuters) - MorphoSys AG ::DGAP-NEWS: ANNUAL GENERAL MEETING OF MORPHOSYS AG ELECTS NEW SUPERVISORY BOARD MEMBERS.SHAREHOLDERS APPROVED ALL RESOLUTIONS PROPOSED BY COMPANY'S MANAGEMENT AT ITS ANNUAL GENERAL MEETING ON THURSDAY.PROPOSAL APPROVED INCLUDE APPOINTMENT OF PRICEWATERHOUSECOOPERS AG AS AUDITOR FOR 2018 FINANCIAL YEAR.  Full Article

Morphosys Says NASDAQ IPO Leads To Total Gross Proceeds Of USD 239 Million
Monday, 23 Apr 2018 

April 23 (Reuters) - MorphoSys AG ::DGAP-NEWS: MORPHOSYS ANNOUNCES CLOSING OF NASDAQ IPO THROUGH AN ADS OFFERING AND EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL ADSS, LEADING TO TOTAL GROSS PROCEEDS OF USD 239 MILLION.SAYS EXPECTS GROSS PROCEEDS OF TRANSACTION TO AMOUNT TO USD 239,006,800.  Full Article

Morphosys ADS Debut At $26.16, Slightly Above IPO Price
Thursday, 19 Apr 2018 

April 19 (Reuters) - MorphoSys AG ::MORPHOSYS AG ADS DEBUT AT $26.16 ON THE NASDAQ VERSUS IPO PRICE OF $25.04/ADS.  Full Article

Morphosys Announces Pricing Of IPO Of American Depositary Shares On Nasdaq
Wednesday, 18 Apr 2018 

April 18 (Reuters) - MorphoSys AG ::MORPHOSYS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES (ADSS) ON NASDAQ.OFFERING PRODUCED GROSS PROCEEDS OF $207.8 MILLION FROM SALE OF 2.07 MILLION NEW ORDINARY SHARES IN FORM OF 8.3 MILLION ADS AT $25.04 PER ADS.  Full Article

German stocks - Factors to watch on Jan. 18

BERLIN, Jan 18 The following are some of the factors that may move German stocks on Friday: